A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
← catalyst calendarNCT06916806 · readout in 259 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Fortrea.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
72estimated
Sites
37
Countries
Canada, China, France +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-01 | actual | When the study began enrolling |
| Primary completion | 2027-05-05 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-09-15 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Systemic Lupus Erythematosus
- Idiopathic Inflammatory Myopathies
- Rheumatoid Arthritis
Intervention
- Drug: AZD5492
Primary outcomes
what the primary-completion date above is the date OFSafety evaluation of AZD5492: Number of participants with treatment-emergent adverse events.
measured Day 1 to end of the study (up to 52 weeks)
Safety evaluation of AZD5492: Number of participants with related treatment-emergent adverse events.
measured Day 1 to end of the study (up to 52 weeks)
Safety evaluation of AZD5492: Frequency of dose limiting toxicities (DLTs).
measured Day 1 to end of the study (up to 52 weeks)
Safety evaluation of AZD5492: Number of SAEs leading to death
measured Day 1 to end of the study (up to 52 weeks)
Safety evaluation of AZD5492: Number of participants with treatment-emergent adverse events by grade.
measured Day 1 to end of the study (up to 52 weeks)
Tolerability evaluation of AZD5492: Number of participants with treatment-emergent vital signs abnormalities.
measured Day 1 to end of the study (up to 52 weeks)
Tolerability evaluation of AZD5492: Number of participants with treatment-emergent clinical laboratory abnormalities.
measured Day 1 to end of the study (up to 52 weeks)
Tolerability evaluation of AZD5492: Number of participants with abnormal ECG.
measured From Day 1 up to Day 180
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed